Obesity and prostate cancer screening in the USA.

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Public Health (Impact Factor: 1.48). 08/2005; 119(8):694-8. DOI: 10.1016/j.puhe.2004.09.002
Source: PubMed

ABSTRACT To estimate the association between body mass index (BMI: kg/m2) and prostate-specific antigen (PSA) cancer screening in a nationally representative sample of US men aged 50 years and older using data from the 2001 Behavioral Risk Factor Surveillance Survey.
Men aged 50 years or older classified by BMI as healthy weight range (18.5-24.9), overweight (25-29.9), obese class I (30-34.9), obese class II (35-39.9), and obese class III (> or =40).
Interval since most recent screening for PSA.
Adjusting for age, race, smoking, education, employment, income and health insurance status, we found that, compared with men in the healthy weight range, men in the overweight [odds ratio (OR)=1.13; 95% confidence interval (95% CI)=1.04-1.35], obese class I (OR=1.26; 95% CI=1.06-1.36) and obese class II (OR=1.14, 95% CI=1.02-1.26) categories were significantly more likely to have obtained a PSA test within the previous year. A similar pattern was observed when we examined other screening intervals (e.g. within past 2 years, within past 3 years, etc.).
Among men aged 50 years and older, overweight and obesity is associated with obtaining a PSA test.

  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: In general population studies, obesity has been associated with risk of high-grade prostate cancer, but little is known about obesity and future prostate cancer risk among men with an initial benign biopsy of the prostate; a high-risk population.METHODS: Within a cohort of 6,692 men followed up after a biopsy or transurethral resection of the prostate (TURP) with benign findings, a nested case-control study was conducted of 494 prostate cancer cases and controls matched on age, race, follow-up duration, biopsy versus TURP and date of procedure. Body mass index at the time of the initial procedure was abstracted from medical records, and initial biopsy specimens were reviewed for the presence of prostatic intraepithelial neoplasia (PIN).RESULTS: Obesity was associated with the presence of PIN in the initial benign specimen [OR = 2.15; 95% confidence interval (CI) 1.13-4.11]. After adjustment for the matching variables, family history of prostate cancer, prostate-specific antigen (PSA) levels at the initial procedure, the number of PSA tests and digital rectal examinations during follow-up, obesity (OR = 1.57; 95% CI, 1.07-2.30) at the time of the initial procedure was associated with prostate cancer incidence during follow-up. Risk associated with obesity was confined to cases with follow-up less than 1,538 days, the median duration of follow-up among cases (OR = 1.95; 95% CI, 1.09-3.48).CONCLUSIONS: Obesity is associated with the presence of PIN in benign specimens and with future prostate cancer risk after an initial benign finding.Impact: Obesity may be a factor to consider when planning clinical follow-up after a benign biopsy. Cancer Epidemiol Biomarkers Prev; 1-7. ©2013 AACR.
    Cancer Epidemiology Biomarkers & Prevention 04/2013; · 4.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Promotion of prostate health remains an essential element of the men's health agenda. Prostatic disease contributes to the rate of morbidity and mortality of men, affecting their quality of life. More than 35 million men have experienced prostatic disease. Each year approximately 200,000 US men will be diagnosed with prostate cancer1 and 30,000 men will die of it.2 In addition to prostate cancer, prostatic disease consists of prostatitis (bacterial, nonbacterial), prostatodynia, and benign prostatic hyperplasia. Prostate cancer remains the predominant condition affecting prostate health.
    The Journal for Nurse Practitioners 09/2005; 1(2):70–71.
  • Journal Français d Ophtalmologie 04/2012; · 0.36 Impact Factor